Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children

Domenico Careddu1
Andrea Pettenazzo2

1Pediatrics, Italian Health Service, Cameri, Italy; 2Department of Women's and Children's Health, University Hospital of Padua, Padova, Italy

Background: In numerous randomized controlled trials (RCTs) and systematic reviews such as those published by the Cochrane Collaboration, Pelargonium sidoides extract EPs® 7630 was shown to be effective in acute respiratory tract infections (aRTI) in all investigated age-groups. This narrative review focuses on recently published results from RCTs investigating the clinical efficacy and safety of EPs 7630 in children and adolescents with different manifestations of aRTI, in order to present a broader overview and to provide an update on the state of knowledge regarding the use of EPs 7630 in this age-group.

Methods: The Cochrane review on P. sidoides extract for aRTI published by the Cochrane Collaboration was searched for cited RCTs with EPs 7630 in children and adolescents suffering from aRTI. A PubMed and SCOPUS literature search was performed for publications issued before June 13, 2017 (search terms: children, Pelargonium sidoides, EPs 7630, respiratory). Reference lists of publications found were searched for relevant citations.

Results: Eight RCTs investigating the application of EPs 7630 in acute bronchitis, acute tonsillopharyngitis, and aRTI in the context of chronic preconditions were identified. Results showed a statistically significant improvement of aRTI symptom severity for EPs 7630 as compared to controls. The investigation of EPs 7630 in asthmatic children and adolescents with aRTI demonstrated a significant symptom-alleviating effect and a possibly associated reduction of asthma attacks. In immunocompromised children with acute upper RTI, an alleviating effect of EPs 7630 was shown. All RCTs reviewed reported good safety and tolerability of EPs 7630.

Conclusion: The P. sidoides extract EPs 7630 is effective and safe for those of pediatric age and may be regarded as an alternative option for the management of aRTI.

Keywords: Pelargonium sidoides, EPs 7630, children, acute respiratory tract infections, acute bronchitis, asthma

Introduction

Pelargonium sidoides, a traditional medicinal plant native to South Africa, shares the same genus (Pelargonium) with the common ornamental geraniums.1 The roots of P. sidoides have centuries-long been used as herbal remedies for respiratory and gastrointestinal infections by the local populations.2-4 Only 120 years ago, it was described by the Englishman Charles Henry Stevens, who praised the root as a new remedy for tuberculosis.5 Identification of numerous compounds of P. sidoides roots, such as prodelphinidins, methoxycurararin, and proanthocyanidins,6 led to the production of an ethanolic extract known as EPs® 7630 (the active ingredient of the product Umckaloabo®, ISO-Arzneimittel, Ettlingen, Germany). Today, the liquid herbal drug preparation EPs...
from the roots of *P. sidoides* (1:8–10), extraction solvent: ethanol 11% (w/w), has been approved for the treatment of acute respiratory tract infections (aRTI) in several countries in Europe, Asia, Australia, and Central and South America.

Documented pharmacological activities of EPs 7630 include antiviral and antibacterial action as well as immune-modulatory capabilities. Several in vitro studies conducted with EPs 7630 showed an inhibitory effect (growth inhibition) against several bacterial strains (*Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, and *Staphylococcus aureus*, especially multi-resistant strains). This effect is brought about by an immune modulation mechanism mediated by the activation of macrophages (with the involvement of cytokine interferon-gamma) and the consequent increase in the production of nitric oxide. The activated macrophages produce, in turn, different cytokines, such as interleukin (IL)-1, IL-2, and tumor necrosis factor-alpha. *P. sidoides* also modulates the production of secretory immunoglobulin A in saliva, IL-15 in the serum and nasal mucosa, and IL-6 in the serum. Biological and pharmacological properties of EPs 7630 are summarized in Figure 1.

The antiviral effect of EPs 7630 is reported to be linked to the production of interferons, although a recent study highlighted a direct antiviral effect on several viruses (influenza, parainfluenza, respiratory syncytial viruses, rhino viruses, coxsackie, and coronaviruses).

The recently published studies by Theisen and Muller and Brown demonstrated an infection-inhibiting effect of EPs 7630. The mode of action is described by Conrad et al and Janecki et al as an exertion of a specific antagonistic effect against the adhesion proteins on the bacterial surface (group A *Streptococcus*), thus preventing adhesion to epithelial cells and subsequent penetration of them. This specific activity appears to be mediated by the proanthocyanidins, which are contained in the extract. Another possible

![Figure 1](https://www.dovepress.com/)

**Figure 1** Mechanism of action of EPs® 7630.

mechanism of protection could be linked to an increase in the ciliary motility of the respiratory epithelium, as shown by preliminary in vitro studies that assessed the effect of EPs 7630 on cultured human respiratory mucosa cells.17

Between 1994 and 2009, ~304 million daily doses of EPs 7630 (4.5 mL of solution or 3 tablets) were sold.14 In addition to the decade-long presence on the international market, the efficacy and safety of EPs 7630 in aRTI have till today been widely demonstrated in several placebo-controlled clinical trials and open clinical studies19 as well as by postmarketing surveillance data.20–22

aRTI are very common in children, and EPs 7630 was shown to be not only an effective but also a safe treatment for these ailments, also for children of preschool age.23 Moreover, based on the available data, the European Respiratory Society has acknowledged *Pelargonium sidoides* root extract as a natural remedy available for the treatment of the symptoms of acute bronchitis (AB).24

In 2013, a review on *P. sidoides* extract for aRTI was published by the Cochrane Collaboration.25 Among the placebo-controlled randomized clinical trials that were available for full evaluation, 4 were conducted in children and adolescents. The aim of the current review is to have a closer look at these trials as well as on further randomized controlled trials (RCTs) published afterward or not included into the Cochrane review in order to provide a current overview of published clinical trials investigating the efficacy of EPs 7630 in children and adolescents suffering from different manifestations of aRTI.

**Materials and methods**

For this narrative review, both open and double-blind RCTs investigating the efficacy of EPs 7630 in children and adolescents suffering from aRTI were eligible. Control groups in eligible trials were allowed to be randomized to either placebo or, in open-label trials, to nonmedication. Clinical trials available for full evaluation were identified from the Cochrane Review authored by Timmer et al.25 In addition, a literature search was performed in the scientific databases PubMed and SCOPUS in order to identify additional eligible trials published afterward or formerly not included in the current Cochrane review. Search terms applied were children, EPs 7630, *Pelargonium sidoides*, respiratory. Publications found were also searched for relevant citations in the respective reference lists.

A total of 8 RCTs were identified and included into our review.26–33 Out of these, 3 RCTs were conducted in the indication AB,26–28 3 RCTs investigated EPs 7630 in children with acute tonsillopharyngitis (ATP),29,31 1 open-label clinical trial studied the treatment of aRTI in children and adolescents suffering from preexisting mild asthma,32 and 1 RCT investigated the effects of the herbal extract on aRTI in immunocompromised children.33

An overview of the clinical trials presented in this review is given in Table 1.

**Results**

**EPs 7630 in treatment of AB**

Three RCTs investigating a total of 820 patients aged between 1 and 18 years and suffering from AB were identified.26–28 AB symptoms were required to have started less than 48 hours prior to admission. As a further selection criterion, symptom severity was required to equal or exceed 5 points on the Bronchitis Severity Scale (BSS; items “coughing”, “pulmonary rales at auscultation”, and “dyspnea”). The BSS is a validated clinical tool for the assessment of the severity of AB on a 5-point scale ranging between 0 “not present” and 4 “very severe”.34,35 All patients were randomized and treated with EPs 7630 or placebo in a double-blind fashion.

Two of the 3 trials found applied similar protocols, which required double-blind randomization using computer-generated encoding with stratification by age, an enrolment visit at baseline (visit 1), an intermediate follow-up visit on days 3–5 (visit 2), and a final follow-up visit on day 7 (visit 3).26,28 The enrolled patients were randomly assigned to treatment with EPs 7630 (age-adjusted dosage: 1 to <6 years: 3×10 drops, 6–12 years: 3×20 drops, >12–18 years: 3×30 drops) or matched placebo. Overall, there were no significant baseline differences between the two treatment groups, neither in demographic nor in anthropometric terms. In 1 trial,26 103 participants received EPs 7630, whereas the placebo group consisted of 97 trial participants. In the other trial,28 111 patients received EPs 7630 and 109 placebo.

The change of the BSS total score between baseline and day 7 was defined as primary efficacy outcome. For safety assessment, adverse events (AE; frequency, nature, and severity) as well as vital parameters and laboratory safety parameters were documented at the scheduled visits.

In both trials, the BSS total score reduction was significantly more pronounced under treatment with EPs 7630 as compared to placebo (*p*<0.0001 each, analysis of covariance [ANCOVA]) (Table 1). Also, the severity reduction regarding the individual BSS items “coughing” and “pulmonary rales at auscultation” at day 7 was significantly more pronounced in the EPs 7630 groups than in the respective placebo groups (*p*<0.0001 in both trials, two-sided t-test). In addition, in both trials, a significantly earlier onset of treatment effect was reported in the EPs 7630 group as compared with the placebo.
Table 1  Randomized controlled trials investigating the efficacy and safety of *Pelargonium sidoides* extract EPs 7630 in children and adolescents with different manifestations of acute respiratory tract infection

<table>
<thead>
<tr>
<th>Trial</th>
<th>Investigation diagnosis</th>
<th>Primary outcome measure</th>
<th>Participants</th>
<th>Intervention*</th>
<th>Results on primary outcome measure (mean total score change ± SD or %)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kamin et al, 2010</td>
<td>AB</td>
<td>BSS</td>
<td>Children and adolescents aged 1–18 years</td>
<td>Age-dependent drops EPs 7630</td>
<td>Day 7: 3.4±1.8 (EPs 7630) 1.2±1.8 (placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n=103) or placebo (n=97), 7 d</td>
<td></td>
</tr>
<tr>
<td>Kamin et al, 2010</td>
<td>AB</td>
<td>BSS</td>
<td>Children and adolescents aged 6–18 years</td>
<td>EPs 7630 3×10 mg/d (n=100) or EPs 7630 3×20 mg/d (n=99) or EPs 7630 3×30 mg/d (n=99) or placebo (n=101), 7 d</td>
<td>Day 7: 3.6±2.4 (EPs 7630 3×10 mg/d) 4.4±1.9 (EPs 7630 3×20 mg/d) 5.0±1.9 (EPs 7630 3×30 mg/d) 3.3±2.6 (placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n=101), 7 d</td>
<td></td>
</tr>
<tr>
<td>Kamin et al, 2012</td>
<td>AB</td>
<td>BSS</td>
<td>Children and adolescents aged 1–18 years</td>
<td>Age-dependent drops EPs 7630</td>
<td>Day 7: 4.4±1.6 (EPs 7630) 2.9±1.4 (placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(n=111) or placebo (n=109), 7 d</td>
<td></td>
</tr>
<tr>
<td>Bereznoy et al, 2003</td>
<td>ATP</td>
<td>TSS</td>
<td>Children aged 6–10 years</td>
<td>EPs 7630 3×20 drops/d (n=73) or placebo (n=70), 6 d</td>
<td>Day 4: 7.1±2.1 (EPs 7630) 2.5±3.6 (placebo)</td>
</tr>
<tr>
<td>Bereznoi et al, 2016</td>
<td>ATP</td>
<td>TSS</td>
<td>Children aged 6–10 years</td>
<td>EPs 7630 3×20 drops/d (n=60) or placebo (n=64), 6 d</td>
<td>Day 4: 6.7±2.7 (EPs 7630) 3.3±4.2 (placebo)</td>
</tr>
<tr>
<td>Timen et al, 2015</td>
<td>ATP</td>
<td>TSS</td>
<td>Children aged 6–10 years</td>
<td>Day 1–2: up to 12×20 drops/d EPs 7630</td>
<td>Responder rates day 4: 90.0% (EPs 7630) 44.7% (placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Day 3–6: 3×20 drops/d EPs 7630 (n=40) or placebo (n=38), 6 d</td>
<td></td>
</tr>
<tr>
<td>Tahan and Yaman, 2013</td>
<td>aRTI with mild asthma</td>
<td>Patient diary</td>
<td>Children and adolescents aged 1–14 years</td>
<td>Age-dependent drops EPs 7630 plus symptomatic treatment (n=30) or symptomatic treatment only (n=31), 5 d</td>
<td>Decreased nasal symptoms day 5: 57% (EPs 7630 plus symptomatic treatment) 26% (symptomatic treatment only) Decreased cough day 5: 44% (EPs 7630 plus symptomatic treatment) 10% (symptomatic treatment only)</td>
</tr>
<tr>
<td>Patiroglu et al, 2012</td>
<td>aRTI with immune-</td>
<td>Parent-filled questionnaires</td>
<td>Children aged 1–5 years</td>
<td>EPs 7630 3×10 drops/d (n=14) or placebo (n=14), 7 d</td>
<td>Without nasal congestion day 7: 71.4% (EPs 7630) 21.5% (placebo)</td>
</tr>
<tr>
<td></td>
<td>deficiency</td>
<td></td>
<td></td>
<td>(n=109) or placebo (n=107)</td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Sample size of the full analysis set. †Full analysis set, last observation carried forward. ‡Values are derived from reference 19.

Abbreviations: AB, acute bronchitis; BSS, Bronchitis Severity Scale; ATP, acute tonsillopharyngitis; TSS, tonsillitis-specific symptoms; aRTI, acute respiratory tract infections; d, day(s).

group (p<0.0001 in both trials, two-sided Mantel–Haenszel χ²-test). By day 4, the onset of treatment effect was reported by 61.1% (EPs 7630) vs 18.5% (placebo)26 and 71.2% (EPs 7630) vs 33.1% (placebo),28 respectively. Accordingly, data reflecting the evaluation of the treatment by both investigators and patients as assessed by the Integrative Medicine Outcomes Scale (IMOS) resulted in a significant advantage for EPs 7630 over placebo in both trials (p<0.0001 in both trials, two-sided Mantel–Haenszel χ²-test). Likewise, the level of satisfaction according to the Integrative Medicine Patient Satisfaction Scale (IMPSS) was better in the EPs 7630 group than the placebo group (p<0.0001 in both trials, two-sided Mantel–Haenszel χ²-test). Measuring changes in health-related quality of life, the questionnaire for health state of children (Fragebogen zum Gesundheitszustand für Kinder [FGK]) highlighted an improvement in well-being in both the EPs 7630 and the placebo group, with a significant advantage for the EPs 7630 group for the item “I am feeling ill” in both trials (p<0.0001 and p=0.0485, respectively, two-sided t-test). In the trial published by Kamin et al,26 EPs 7630 significantly exceeded the results of placebo in all items assessed (p<0.0002, two-sided t-test).

Between baseline and day 7, the number of patients on bed rest was reduced markedly in both treatment groups with an advantage for those patients receiving EPs 7630 treatment in both RCTs. Out of those patients who were treated with EPs 7630, a clearly higher proportion was able to attend work, school, or kindergarten by day 7 than this was the case in the respective placebo groups (48.5% vs 12.4%27 and 57.7% vs 17.4%,29 respectively).

In both trials, EPs 7630 was well tolerated. There were no intergroup differences found concerning laboratory parameters during the treatment period. AE incidence was only slightly higher in the active treatment groups as compared to placebo with most AEs being reported as gastrointestinal complaints. None of the AEs reported was serious.
The third RCT identified was a dose-finding study investigating the efficacy and tolerability of 3 different doses of EPs 7630 in children and adolescents with AB including patients aged between 6 and 18 years. Inclusion criteria were similar to the two above-described RCTs. A total of 400 patients were randomized to treatment with 3×10 mg (101 patients), 3×20 mg (99 patients), or 3×30 mg (99 patients) EPs 7630 or matched placebo (101 patients) daily for 7 days. The full analysis set for efficacy evaluation consisted of 399 trial participants. Primary outcome measure was the validated BSS (items “coughing”, “sputum production”, “pulmonary rales at auscultation”, “chest pain while coughing”, and “dyspnea”).

Pairwise comparisons of each EPs 7630 group with placebo using the ANCOVA model showed statistically significant differences in the BSS total score reduction at day 7 for the EPs 7630 (60 mg) and the EPs 7630 (90 mg) groups (p<0.0004 and p<0.0001, respectively, two-sided ANCOVA p-values) (Table 1). Regarding the individual BSS items, statistically significant advantages of EPs 7630 were found for the 60 mg and 90 mg groups for the symptoms “coughing” (p=0.0433 and p=0.0002, respectively), “sputum production” (p=0.0499 and p=0.0048, respectively), and “pulmonary rales at auscultation” (p=0.0014 and p<0.0001, respectively, two-sided t-test, each). Furthermore, a statistically significant advantage with respect to treatment effect onset as reported by the trial participants was found for the EPs 7630 (60 mg) and EPs 7630 (90 mg) groups (p=0.0060 and p<0.0001, respectively, two-sided Mantel–Haenszel χ²-test). Both investigators and patients evaluated the treatment outcome under EPs 7630 significantly better than that achieved under placebo (IMOS). Likewise, patient satisfaction with the treatment as assessed by the IMPSS was also better in the EPs 7630 groups, as were outcomes reflecting the change of health-related quality of life (FGK) between day 0 and day 7. This improvement was more pronounced in the EPs 7630 (60 mg) and EPs 7630 (90 mg) groups compared with the placebo group with significant advantages of the EPs 7630 (60 mg) and EPs 7630 (90 mg) group over placebo for the FGK item “I am feeling ill” (p=0.0012 and p<0.0001, respectively, two-sided t-test).

The ability to perform daily life activities improved greatest in the EPs 7630 (90 mg) group with 53.5% of the patients being able to attend work, school, or kindergarten again by day 7. Of those who were administered 60 mg/d EPs 7630, 44.4% were back to their daily activities by day 7, whereas patients of the EPs 7630 (30 mg) and placebo groups achieved nearly comparable results with 35.0% and 33.7%, respectively.

Safety measures performed in this RCT show that EPs 7630 was well tolerated. Incidence and severity of AEs in all dose groups investigated were low and comparable with those reported in the placebo group. Based on the efficacy and safety results obtained in this dose-finding study, a daily dose of 60 mg EPs 7630 was suggested to be the optimal dose to be applied in children and adolescents with AB.

**EPs 7630 in the treatment of acute, non-beta-hemolytic tonsillopharyngitis**

Three RCTs investigating the efficacy and tolerability of EPs 7630 in a total of 346 children aged 6–10 years suffering from ATP were identified.

Two of these trials, which included 143 and 124 children, respectively, followed comparable protocols. Children were randomized to a 6-day treatment with either 3×20 drops/d EPs 7630 or matched placebo, the respective distributions being 73 vs 72 and 60 vs 64. In both RCTs, primary outcome measure was the decrease of tonsillitis-specific symptoms (TSS), which included the items “difficulty in swallowing”, “sore throat”, “salivation”, “redness of the throat”, and “fever”, measured on a 4-point scale. Fever was classified as ≤37.5°C=0; 37.5°C to <38.5°C=1; 38.5°C to <39.5°C=2; and ≥39.5°C=3. The other symptoms were assessed by the categories “severe” (3), “moderate” (2), “mild” (1), and “not present” (0). Thus, a maximum total score of TSS of 15 points was possible. The change of the TSS total score between baseline and day 4 was evaluated as the primary endpoint.

In both RCTs, the reduction of the TSS total score at day 4 was significantly more pronounced in the active treatment groups as compared to their respective placebo control groups (p<0.0001 and p<0.001, respectively, ANCOVA) (Table 1). In the trial reported by Bereznoy et al., a significant difference between the TSS total score reduction rates measured in the EPs 7630 and in the placebo group, respectively, with superiority of the herbal drug extract, was already shown for the first interim visit (day 2). Furthermore, the onset of treatment effect as reported by the members of the active treatment group was significantly superior to placebo already by day 1–2 (23% vs 1.4%). Accordingly, the proportion of patients who did not need bed rest anymore by day 6 was 87.7% in the EPs 7630 group and 38.6% in the placebo group. Data obtained from the second RCT published by Bereznoi et al. furthermore revealed that the concomitant use of paracetamol...
confirmed by a recently published meta-analysis of the data19 obtained from these two trials. The meta-analysis also showed a significant advantage of EPs 7630 with regard to complete symptom recovery at day 4.

The third RCT31 included 78 children with nonbeta-hemolytic ATP. The primary endpoint for assessing the efficacy of EPs 7630 compared to placebo was the proportion of responders (success of therapy) with response being defined by a TSS total score ≤4 points as measured after 4 days of treatment. Trial participants were included upon presentation of a TSS total score of ≥6 points with complaints lasting no longer than 48 hours at treatment start (day 0). TSS (“dysphagia”, “sore throat”, “salivation”, “reddening”, “coating left”, “coating right”, and “fever”) were assessed. Local symptoms were assessed by the categories “severe” (3), “moderate” (2), “mild” (1), and “no symptom” (0); values for fever were ≤37.5°C=C=0; 37.5°C to <38.5°C=C=1; 38.5°C to <39.5°C=C=2; >39.5°C=C=3. Thus, a maximum TSS total score of 21 points was possible. As a dosing regimen, the active treatment group (40 children) received 20 drops of EPs 7630 hourly while awake (up to 12×20 drops/d) on the first 2 days of treatment, and then 3×20 drops/d on days 3–6. Placebo was administered accordingly in the control group (38 children).

Results showed that the rate of patients with successful therapy was 90.0% in the EPs 7630 group and 44.7% in the placebo group, respectively (p<0.001, Fisher’s exact test), corresponding to a number needed to treat of 2.21. The difference between the EPs 7630 group and the placebo group with respect to TSS total score was significant as from day 2 onward (p<0.001, Wilcoxon test). Accordingly, concomitant consumption of paracetamol, which was allowed in case of fever ≥38.5°C, was documented for 35.0% of the EPs 7630 group members and for 47.4% of the members of the placebo group.

EPs 7630 was well tolerated, even when the administered amount exceeded the daily dosage of 3×20 drops recommended for children aged 6–12 years. Serious AEs did not occur.

**EPs 7630 in the treatment of aRTI in the context of chronic preconditions**

An open monocentric clinical trial32 investigated if EPs 7630 could affect the frequency of asthma attacks during viral respiratory tract infection in asthmatic children and adolescents aged 1–14 years. A total of 61 patients suffering from mild asthma (according to the Global Initiative for Asthma 2010 classification) and presenting with viral upper respiratory tract infection were randomly assigned to either EPs 7630 plus symptomatic treatment or symptomatic treatment only. For symptomatic treatment, paracetamol was given. The primary outcome variable was the change in severity and duration of respiratory symptoms; secondary outcome variable was the frequency of asthma attacks. Starting on day 1 and continuing to day 5, patients in the EPs 7630 group were administered 3×10 drops/d (between 1 and 5 years of age), 3×20 drops/d (6–12 years), and 3×30 drops/d (over 12 years), respectively, as well as paracetamol on demand. The second group received only paracetamol on demand. All participants ran patient diaries for documentation of symptom severity over the treatment period. Patient diary entries were evaluated after 5 days of treatment. A blood laboratory test was performed on all patients for eosinophils and immunoglobulin E dosage as well as spirometry and prick test.

Evaluation of the patient diary entries on day 5 showed that treatment with EPs 7630 was associated with a significant reduction in nasal symptoms and frequency of cough (p<0.05, χ²-test). Asthma attacks were also significantly reduced in the EPs 7630 group compared to placebo (6 vs 15 attacks) (p<0.05, χ²-test) (Table 1). Further studies are needed to confirm these results.

One further RCT33 was designed as a monocentric pilot study and evaluated the efficacy of EPs 7630 in the treatment of symptoms of upper airways infection in children aged between 1 and 5 years suffering from transient hypogammaglobulinemia of infancy (THI). A total of 28 patients with THI who were suffering from aRTI at the time of trial admission were randomized to either EPs 7630 (14 patients) or placebo treatment (14 patients), respectively. Blood laboratory tests were performed before and after the 1-week treatment period. Parents or legal guardians of the trial participants were asked to daily document the development of aRTI symptoms during the treatment period using a 9-item questionnaire to be answered by means of a 2-point scale. Items assessed by the questionnaire were “general state of health”, “nasal congestion”, “appetite”, “daily cough frequency”, “nocturnal cough frequency”, “fever”, “pain”, “sleep pattern”, and “additional symptoms”.

In this trial, statistically significant results were seen for EPs 7630 concerning improvement of appetite and nasal congestion.

In both these trials conducted in the context of chronic preconditions, a good tolerability and safety of EPs 7630 could be seen.
Discussion and conclusion
Numerous clinical trials have widely shown the efficacy of the *P. sidoides* preparation EPs 7630 in reducing the symptoms resulting from infection of the airways, from common cold to AB, in the adult population. The early administration of EPs 7630 has been shown not only to reduce the severity of symptoms but also to preclude the start of symptom improvement, with a reduction of illness duration and an earlier resumption of usual activities in the patients affected.

The trials conducted on pediatric patients that were presented in this review have essentially confirmed the results already observed in the adult population with regard to efficacy and safety of use. These data allow us to make some considerations that are particularly applicable to the pediatric age: pathologies affecting the airways are the reason for frequent requests for medical assessment and substantial drug prescription; the use of antibiotics for this type of pathology is extremely common, especially when there is a persistent high temperature, even if the etiology is typically viral. The early use of EPs 7630 at the onset of signs of respiratory infection reduces or resolves symptoms more rapidly, reduces the risk of bacterial superinfection, allows more rapid functional recovery, and reduces the use of other drugs such as paracetamol, or, most importantly, antibiotics, to counter the increasingly worrying phenomenon of antibiotic resistance. EPs 7630 is well tolerated and can be used in children from the age of 1 year. Furthermore, its use could provide preventive action against clinical worsening or complications, while reducing the need for NSAIDs and antibiotics.

Disclosure
The authors report no conflicts of interest in this work.

References